Compass sets up full COMPANION-002 data unveil after tovecimig hit ORR, PFS
Compass Therapeutics will present the complete COMPANION-002 dataset, including duration of response, later in 2026, building on an already-disclosed 17.1% response rate and a 56% reduction in progression risk for tovecimig in second-line biliary tract cancer.
Executive Summary
- Compass Therapeutics will present the full COMPANION-002 dataset, including duration of response, at a medical conference later this year, adding detail to efficacy results the company already disclosed.
- Tovecimig combined with paclitaxel already met the trial's primary and key secondary endpoints, cutting the risk of disease progression and nearly tripling response rate versus paclitaxel alone.
- High crossover from the control arm into the treatment arm undercut the trial's ability to draw a clean survival conclusion, a limitation the company disclosed alongside its positive results.
- Compass is treating this data package as the basis for a first BLA filing, positioning the upcoming full presentation as a regulatory-facing event rather than pure scientific disclosure.
The presentation
Compass Therapeutics said it will present the complete COMPANION-002 dataset, including duration of response (DoR), at a medical conference later in 2026, according to the company's April 27, 2026 disclosure. The trial, registered as NCT05506943, is a randomized Phase 2/3 study testing tovecimig (CTX-009) plus paclitaxel against paclitaxel alone in adults with unresectable advanced, metastatic or recurrent biliary tract cancer previously treated with a first-line gemcitabine and platinum regimen. The study enrolled 168 patients and is registrational. Tovecimig+1Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 ...Apr 27, 2026A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The results already in hand
Tovecimig plus paclitaxel met the trial's primary endpoint of overall response rate, posting 17.1% versus 5.3% for paclitaxel alone (p=0.031). The combination also met the key secondary endpoint of progression-free survival, at 4.7 months versus 2.6 months, a 56% reduction in the risk of progression (hazard ratio 0.44, p<0.0001). Compass Chief Executive Officer Thomas Schuetz, MD, PhD, called the progression-risk reduction "unprecedented in this patient population without an actionable mutation in their tumor". TovecimigTovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 ...Apr 27, 2026
The survival confound
Overall survival did not reach statistical significance because 54% of patients randomized to the control arm crossed over to receive tovecimig after progressing. In a subset analysis limited to the control arm, crossover patients had a median overall survival of 12.8 months against 6.1 months for those who did not cross over (hazard ratio 0.54, p=0.04). Across the full study, 85% of patients ultimately received tovecimig, and the pooled median overall survival for all patients was 8.9 months. TovecimigTovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 ...Apr 27, 2026
Regulatory path
Tovecimig holds FDA Fast Track Designation, granted in 2024, and received Orphan Drug Designation in April 2026 for second-line biliary tract cancer. Compass said it plans to meet with the FDA ahead of a planned Biologics License Application submission, framing the upcoming full-data presentation as a step toward that filing rather than a standalone scientific update. TovecimigTovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 ...Apr 27, 2026
The competitive field
No other trial in biliary tract cancer combines a DLL4 x VEGF-A bispecific antibody with chemotherapy in the second-line setting; the closest activity in the indication comes from checkpoint inhibitors such as durvalumab and envafolimab and small molecules like apatinib, none of which share tovecimig's target or mechanism class. That leaves tovecimig without a direct mechanistic comparator in this population, so the upcoming duration-of-response data will be read against paclitaxel-alone benchmarks in this trial rather than against a rival bispecific. NCT05506943A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943
Trial operations
The study's primary completion date has moved twice, from December 2023 to July 2025 and then to December 2026, while enrollment grew from a 120-patient target to 168 actual patients, changes the operational model treats as within the routine band for a design of this kind. ClinicalTrials.gov briefly listed the trial as Completed on April 30, 2026, before reverting it to Active, not recruiting on May 7, 2026, alongside the primary completion date update, consistent with a sponsor still finalizing data collection ahead of the conference presentation. NCT05506943A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.